What litigation is happening around Korlym (mifepristone)?
Korlym (mifepristone) faces ongoing legal pressure tied to generic competition. The relevant dispute centers on whether generic versions can be approved and marketed while Korlym’s patent and regulatory protections are still in force, and on whether those protections can be invalidated or design-arounded.
In the U.S., these disputes typically play out through Hatch-Waxman-type filings (often including Paragraph IV challenges to patents listed in the FDA’s Orange Book). Those cases determine whether the U.S. approval pathway can proceed during the protection period and whether a generic can launch at risk or only after a court date/patent expiry.
How do generic challenges affect Korlym’s market timeline?
When a generic applicant files a patent challenge, it can trigger an automatic stay tied to the first court action and the specific procedural posture. If the patent is ultimately held not infringed or invalid, the generic may gain the ability to launch sooner than it otherwise would have. If the court rules for the brand, generics typically must wait until the challenged patents expire or are otherwise no longer barriers.
The practical result is that Korlym’s launch and pricing dynamics can be influenced by court timing even if no final “end of exclusivity” date has passed yet.
Which patents are usually challenged in Korlym cases?
In generics cases involving a branded product, the challenged patents are commonly ones covering formulation, method of use, dosing regimens, or other claimed aspects of the drug. The litigation focuses on whether the generic product infringes those claims and whether the claims are invalid under patent law (for example, for obviousness, lack of novelty, or inadequate disclosure).
The specific patents and claim numbers matter because “design-around” strategies can let a generic enter without matching the exact disputed claim elements, or because different claims can survive even if others fall.
Are there “at-risk” launches, and what happens if a generic launches before winning?
If a generic company wins permission to launch (or a stay expires due to procedural developments) but later loses on appeal or on validity/infringement, the generic can face damages exposure and possible injunctions. Conversely, if the brand keeps the stay in place or wins key rulings, the generic may be blocked from entering during the protection window.
Because patent litigation can last years, these cases often include parallel motion practice (preliminary/injunction-related requests, claim construction, summary judgment) that can shift expectations even before a final merits decision.
Where does ongoing litigation leave patients and prescribers?
For patients, the key issue is whether a lower-cost generic option will become available during ongoing proceedings. For prescribers, the question is often operational: whether a generic introduction is imminent, whether substitution is likely, and how quickly payers will adjust coverage once approval is granted.
Even with approval, payers may require prior authorization or restrict coverage until generic pricing and contracting stabilize—so litigation outcomes can indirectly affect access.
What to check for the latest status
To track “ongoing” Korlym litigation accurately, the most reliable approach is to look up:
- The most recent court docket entries for the specific Korlym patent case(s)
- Updates tied to FDA Orange Book-listed patents
- Any generic applicant’s most recent filings tied to infringement/invalidity arguments
If you share the jurisdiction (e.g., Delaware, New Jersey) or the names of the generic applicants you’re seeing referenced, I can narrow the answer to the particular Korlym case(s) and what stage each appears to be in.
Sources
No sources were provided in the prompt.